Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release

Cancer Science

Volumn 101, Issue 9, 2010, Pages 1939-1946

  Sato, Akiko ^a   Tamura, Yasuaki ^a   Sato, Noriyuki ^a   Yamashita, Toshiharu ^a   Takada, Tomoaki ^a   Sato, Makito ^a   Osai, Yasue ^a   Okura, Masae ^a   Ono, Ichiro ^a   Ito, Akira ^b   Honda, Hiroyuki ^c   Wakamatsu, Kazumasa ^d   Ito, Shosuke ^d   Jimbow, Kowichi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 S CYSTEAMINYLPHENOL; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 72; MAGNETITE; N PROPIONYL 4 S CYSTEAMINYLPHENOL; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL LYSATE; CHEMOTHERMOIMMUNO THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; HYPERTHERMIA; IMMUNE RESPONSE; MAGNETIC FIELD; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CROSS-PRIMING; CYSTAMINE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ELECTROMAGNETIC FIELDS; FEMALE; HEAT-SHOCK PROTEINS; HOT TEMPERATURE; HSP72 HEAT-SHOCK PROTEINS; HYPERTHERMIA, INDUCED; MAGNETITE NANOPARTICLES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PEPTIDES; PHENOLS; PROTEIN BINDING; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77955934191     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01623.x     Document Type: Article

References (28)

1. Balch CM, Buzaid AC, Soong SJ. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-48.
2. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 1998, 89:463-9.
3. Kawai N, Ito A, Nakahara Y. Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 2005, 64:373-81.
4. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 2005, 100:1-11.
5. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res 1998, 89:775-82.
6. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001, 50:515-22.
7. Ito A, Kobayashi T, Honda H. A mechanism of antitumor immunity induced by hyperthermia. Jpn J Hyperthermic Oncol 2005, 21:1-19.
8. Ito A, Takeshi K. Intracellular hyperthermia using magnetite nanoparticles: a novel method for hyperthermia clinical applications. Thermal Medicine 2008, 24:113-29.
9. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 1996, 87:1179-83.
10. Hergt R, Dutz S, Mueller R, Zeisberger M. Magnetite particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J Phys Condens Matter 2006, 18:S2919-34.
11. Ito A, Shinkai M, Honda H. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003, 52:80-8.
12. Ito A, Matsuoka F, Honda H, Kobayashi T. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother 2004, 53:26-32.
13. Ito A, Honda H, Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother 2006, 55:320-8.
14. Ito Y, Jimbow K. Selective cytotoxicity of 4-S-cysteaminylphenol on follicular melanocytes of the black mouse: rational basis for its application to melanoma chemotherapy. Cancer Res 1987, 47:3278-84.
15. Miura S, Ueda T, Jimbow K, Ito S, Fujita K. Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect. Arch Dermatol Res 1987, 279:219-25.
16. Miura T, Jimbow K, Ito S. The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative. Int J Cancer 1990, 46:931-4.
17. Thomas PD, Kishi H, Cao H. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. J Invest Dermatol 1999, 113:928-34.
18. Sato M, Yamashita T, Ohkura M. N-propionyl- cysteaminylphenol -magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells. J Invest Dermatol 2009, 129:2233-41.
19. Takada T, Yamashita T, Sato M. Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy. J Biomed Biotechnol 2009, 2009:457936.
20. Mise K, Kan N, Okino T. Effect of heat treatment on tumor cells and antitumor effector cells. Cancer Res 1990, 50:6199-202.
21. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998, 10:609-17.
22. Ito A, Matsuoka F, Honda H, Kobayashi T. Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles. Cancer Gene Ther 2003, 10:918-25.
23. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994, 152:5398-403.
24. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278:117-20.
25. Moroi Y, Mayhew M, Trcka J. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000, 97:3485-90.
26. Kurotaki T, Tamura Y, Ueda G. Efficient Cross-Presentation by Heat Shock Protein 90-Peptide Complex-Loaded Dendritic Cells via an Endosomal Pathway. J Immunol 2007, 179:1803-13.
27. Kutomi G, Tamura Y, Okuya K. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen-regulated protein 150-peptide complexes. J Immunol 2009, 183:5861-9.
28. Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 2004, 21:155-65.